https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53913 Wed 28 Feb 2024 15:58:52 AEDT ]]> Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47009 Tue 13 Dec 2022 11:34:29 AEDT ]]> PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55040 Thu 04 Apr 2024 13:51:52 AEDT ]]> Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50946 Mon 14 Aug 2023 14:01:12 AEST ]]> ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53140 Fri 17 Nov 2023 11:42:18 AEDT ]]> Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51529 Fri 08 Sep 2023 12:10:33 AEST ]]>